Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Reference-controlled, Dose Escalating Study to Examine the Pharmacokinetics and Safety of AeroVanc Inhalation Powder.

NCT01537666 is registered in ClinicalTrials.gov with Savara Inc. as lead sponsor.

NCT NCT01537666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01537666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Reference-controlled, Dose Escalating Study to Examine the Pharmacokinetics and Safety of AeroVanc Inhalation Powder.
Lead sponsor
Savara Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2011
Completion date
March 31, 2012
Enrollment
25 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis, healthy